Format

Send to

Choose Destination
Diabetes Care. 2009 May;32(5):810-2. doi: 10.2337/dc08-1736. Epub 2009 Feb 19.

Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients.

Author information

1
School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia.

Abstract

OBJECTIVE:

The vascular benefits of statins might be attenuated by inhibition of coenzyme Q(10) (CoQ(10)) synthesis. We investigated whether oral CoQ(10) supplementation improves endothelial dysfunction in statin-treated type 2 diabetic patients.

RESEARCH DESIGN AND METHODS:

In a double-blind crossover study, 23 statin-treated type 2 diabetic patients with LDL cholesterol <2.5 mmol/l and endothelial dysfunction (brachial artery flow-mediated dilatation [FMD] <5.5%) were randomized to oral CoQ(10) (200 mg/day) or placebo for 12 weeks. We measured brachial artery FMD and nitrate-mediated dilatation (NMD) by ultrasonography. Plasma F(2)-isoprostane and 24-h urinary 20-hydroxyeicosatetraenoic acid (HETE) levels were measured as systemic oxidative stress markers.

RESULTS:

Compared with placebo, CoQ(10) supplementation increased brachial artery FMD by 1.0 +/- 0.5% (P = 0.04), but did not alter NMD (P = 0.66). CoQ(10) supplementation also did not alter plasma F(2)-isoprostane (P = 0.58) or urinary 20-HETE levels (P = 0.28).

CONCLUSIONS:

CoQ(10) supplementation improved endothelial dysfunction in statin-treated type 2 diabetic patients, possibly by altering local vascular oxidative stress.

PMID:
19228872
PMCID:
PMC2671099
DOI:
10.2337/dc08-1736
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center